Epidemiological Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Use in Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) in Terms of Second Line (2L) Treatment: An Ad Hoc Analysis from the POLARIX Study
| Autor: | Frédéric Boissard, Hervé Tilly, Georg Lenz, Graham P. Collins, Antonio Pinto, Laurie H. Sehn, Gilles Salles, Mathilde Roussel, Leonardo Simonella, Rodrigo Ho, Jamie Hirata, Calvin Lee, Anthony Masaquel, Aino Launonen |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Blood. 140:6645-6647 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood-2022-157904 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|